FDA denies Ocaliva full approval, but Intercept hopes to keep drug on marketnews2024-11-12T19:14:56+00:00November 12th, 2024|Endpoints News|
AstraZeneca, Daiichi Sankyo replace lung cancer filing for Enhertu successornews2024-11-12T12:21:18+00:00November 12th, 2024|Endpoints News|
Bayer not eyeing new deals to address Xarelto sales erosionnews2024-11-12T12:21:04+00:00November 12th, 2024|Endpoints News|
GSK acquires Parkinson’s small molecule from Vesaliusnews2024-11-12T11:30:30+00:00November 12th, 2024|Endpoints News|
23andMe to shut down its therapeutics divisionnews2024-11-11T23:44:13+00:00November 11th, 2024|Endpoints News|
Rapt cuts immunology program following clinical holdsnews2024-11-11T20:33:45+00:00November 11th, 2024|Endpoints News|
FDA lifts hold on Novavax vaccines after adverse event reclassified as ALSnews2024-11-11T18:25:04+00:00November 11th, 2024|Endpoints News|
ALK-Abelló licenses ARS’ anaphylaxis nasal spray in certain markets for $145Mnews2024-11-11T12:20:00+00:00November 11th, 2024|Endpoints News|
Updated: FDA approves Autolus’ CAR-T cell therapy for aggressive blood cancernews2024-11-11T08:09:09+00:00November 11th, 2024|Endpoints News|
FDA action puts Chinese API manufacturer on import block listnews2024-11-08T20:09:48+00:00November 8th, 2024|Endpoints News|
